Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.12+0.04 (+0.66%)
Close on Nov 17, 2026Market cap $185.16MP/E –Yield –
Cartesian Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cartesian Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$155.36M. For fiscal 2025 it was -$143.41M. The highest annual figure on record is $14.54M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$143.41M | – |
| FY2024 | Dec 31, 2024 | -$43.90M | – |
| FY2023 | Dec 31, 2023 | -$86.42M | -694.4% |
| FY2022 | Dec 31, 2022 | $14.54M | – |
| FY2021 | Dec 31, 2021 | -$4.60M | – |
| FY2020 | Dec 31, 2020 | -$56.82M | – |
| FY2019 | Dec 31, 2019 | -$52.46M | – |
| FY2018 | Dec 31, 2018 | -$65.02M | – |
| FY2017 | Dec 31, 2017 | -$63.78M | – |
| FY2016 | Dec 31, 2016 | -$34.67M | – |
| FY2015 | Dec 31, 2015 | -$25.30M | – |
| FY2014 | Dec 31, 2014 | -$15.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$78.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.07M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.81M | -258.5% |
| Q1 FY2025 | Mar 31, 2025 | -$21.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.58M | – |
| Q2 FY2024 | Jun 30, 2024 | $13.76M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$36.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.07M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.64M | -234.5% |
| Q1 FY2023 | Mar 31, 2023 | -$18.38M | -270.6% |
| Q4 FY2022 | Dec 31, 2022 | -$8.50M | -308.3% |
| Q3 FY2022 | Sep 30, 2022 | -$1.60M | – |
| Q2 FY2022 | Jun 30, 2022 | $13.86M | +2966.4% |
| Q1 FY2022 | Mar 31, 2022 | $10.77M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.97M | – |
| Q2 FY2021 | Jun 30, 2021 | $452.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.16M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.90M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.73M | – |
| Q2 FY2020 | Jun 30, 2020 | -$16.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.82M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.57M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.79M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.24M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -$14.50M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.94M | – |
| Q2 FY2018 | Jun 30, 2018 | -$18.77M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.81M | – |
| Q4 FY2017 | Dec 31, 2017 | -$19.28M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.85M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.87M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.78M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.86M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.47M | – |
See a number that looks wrong?